ProCE Banner Activity

A.R.R.O.W. Phase III Trial of Once- vs Twice-Weekly Carfilzomib + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
Median PFS and ORR significantly improved with once- vs twice-weekly dosing of carfilzomib + dexamethasone in patients with relapsed/refractory multiple myeloma.

Released: June 07, 2018

Expiration: June 06, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen